AARD: SEC Form 8-K filed by Aardvark Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for AARD
Across the 23 sessions after earlier AARD headlines, the stock closed higher 6 times and lower 17 times, with a median move of 5.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AARD | SPY |
|---|---|---|---|
| Oct 23, 2026 | Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data | -64.8% | -0.5% |
| Oct 9, 2026 | AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm | +1.1% | +0.6% |
| Oct 8, 2026 | Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | -5.0% | -0.4% |
| Oct 5, 2026 | Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +4.6% | +0.7% |
| Aug 12, 2026 | Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | -8.6% | +0.3% |
| May 15, 2026 | Aardvark Therapeutics downgraded by Morgan Stanley with a new price targetand 1 other headline that session | -32.1% | -1.2% |
Keep researching AARD
- What is Form 8-K?The SEC "current report" a public company files to disclose material events, generally within four business days of the event.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- AARD insider tradesEvery buy and sale reported by Aardvark Therapeutics Inc. officers, directors and large holders.
- AARD earnings historyPast Aardvark Therapeutics Inc. earnings releases, newest first.
- AARD financial statementsRevenue, profit, cash flow and balance sheet from Aardvark Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
AARD
Aardvark Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for AARD
Full AARD profile on Quantisnow Follow AARD and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time